Furthermore, BAL flow cytometry identifies CD8+ T lymphocytes as protective mediators against pulmonary fibrosis and mortality, highlighting their potential as prognostic biomarkers of disease severity in HP and identifying them as promising targets for therapeutic strategies aimed at mitigating fibrosis progression in interstitial lung disease. The gene discussed is CD8A; the disease is pulmonary fibrosis.